IMAB Stock - I-Mab
Unlock GoAI Insights for IMAB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $4.49M | $-10,697,247 | $88.03M | $1.54B |
| Gross Profit | N/A | $4.49M | $-248,800,000 | $41.59M | $1.54B |
| Gross Margin | N/A | 100.0% | 2325.8% | 47.3% | 100.0% |
| Operating Income | $-375,358,000 | $-511,162,000 | $-366,078,000 | $-2,071,307,000 | $155.57M |
| Net Income | $-162,257,000 | $-1,465,694,000 | $-2,507,317,000 | $-2,331,541,000 | $470.92M |
| Net Margin | N/A | -32674.0% | 23438.9% | -2648.7% | 30.5% |
| EPS | $-4.46 | $-17.62 | $-30.38 | $-30.70 | $8.07 |
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 3rd 2025 | Leerink Partners | Initiation | Outperform | $9 |
| September 9th 2025 | BTIG Research | Initiation | Buy | $7 |
Earnings History & Surprises
IMABEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 1, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.06 | $-0.25 | -316.7% | ✗ MISS |
Q3 2025 | Aug 20, 2025 | $-0.10 | $-0.07 | +30.0% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.06 | $-0.04 | +33.3% | ✓ BEAT |
Q2 2025 | Apr 3, 2025 | $-0.01 | $-0.00 | +72.0% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.16 | $-0.25 | -56.3% | ✗ MISS |
Q3 2024 | Aug 28, 2024 | $-0.51 | $-0.07 | +86.3% | ✓ BEAT |
Q2 2024 | Apr 30, 2024 | — | $-0.26 | — | — |
Q1 2024 | Mar 29, 2024 | $-0.10 | $0.02 | +116.2% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | — | $-0.25 | — | — |
Q3 2023 | Aug 17, 2023 | $-0.26 | $-0.28 | -7.2% | ✗ MISS |
Q2 2023 | May 1, 2023 | — | $-0.56 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.29 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-0.41 | — | — |
Q3 2022 | Aug 30, 2022 | $-0.16 | $-0.54 | -235.0% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-0.34 | $-0.44 | -28.3% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | — | $-0.54 | — | — |
Q2 2021 | Apr 28, 2021 | — | $0.98 | — | — |
Q1 2021 | Feb 5, 2021 | $-0.09 | $0.01 | +114.9% | ✓ BEAT |
Q3 2020 | Aug 31, 2020 | $-0.53 | $-0.34 | +36.1% | ✓ BEAT |
Latest News
I-Mab Changes Name To NovaBridge Biosciences; To Trade Under New Name, NBP Ticker, Effective Oct. 30
➖ NeutralBTIG Reiterates Buy on I-MAB, Maintains $9 Price Target
📈 PositiveI-Mab Reports 18% Response Rate For Givastomig Monotherapy In Heavily Pretreated Gastric Cancer; Phase 2 Trial To Launch In 2026; To Present Data At 2025 AACR-NCI-EORTC Molecular Targets And Cancer Therapeutics Conference On October 23, 2025
📈 PositiveBTIG Maintains Buy on I-MAB, Raises Price Target to $9
📈 PositiveI-MAB shares are trading lower. The company announced its intention to pursue a dual list an IPO in Hong Kong and the Nasdaq.
➖ NeutralI-Mab tumbles after announcing new business model
📉 NegativeTrading Halt: Halt status updated at 4:20:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralI-Mab Laucnhes New Business Model Focused On Leveraging Its Global Capabilities To Accelerate Access To Innovative Medicines And Drive Strategic Growth. Company Plans A Dual Listing IPO In Hong Kong And Nasdaq And Will Operate Under The New Name Novabridge Biosciences
📈 PositiveTrading Halt: Halted at 4:01:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralI-Mab to Present Updated Phase 1 Givastomig Data in Gastroesophageal Cancer at Major Oncology Conference
📈 PositiveI-MAB shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and a $9 price target.
📈 PositiveLeerink Partners Initiates Coverage On I-MAB with Outperform Rating, Announces Price Target of $9
📈 PositiveBTIG Reiterates Buy on I-MAB, Maintains $7 Price Target
📈 PositiveBTIG Initiates Coverage On I-MAB with Buy Rating, Announces Price Target of $7
📈 PositiveNeedham Reiterates Buy on I-MAB, Maintains $6 Price Target
📈 PositiveI-Mab Accelerates Givastomig Development With Global Phase 2 Trial In Metastatic Gastric Cancer; Expands Pipeline, And Appoints Wei Fu As Executive Chairman
📈 PositiveI-Mab Strengthens Leadership With New Board Appointments, Research And Development Committee Formation, And Expansion Of Scientific Advisory Board
📈 PositiveI-MAB shares are trading higher on possible continued strength after reporting a year-over-year increase in Q2 EPADS results on Wednesday. Additionally, Needham raised its price target on the stock from $5 to $6 on Thursday.
📈 PositiveHC Wainwright & Co. Reiterates Buy on I-MAB, Maintains $7 Price Target
📈 PositiveNeedham Maintains Buy on I-MAB, Raises Price Target to $6
📈 PositiveFrequently Asked Questions about IMAB
What is IMAB's current stock price?
What is the analyst price target for IMAB?
What sector is I-Mab in?
What is IMAB's market cap?
Does IMAB pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IMAB for comparison